Pharma News 10_03 posted on October 3, 2008Is Eli Lilly the "mystery suitor" for ImClone? - Eli Lilly & Co. is in advanced talks to buy cancer-drug developer ImClone Systems for $70 a share, or $6.1 billion, The Wall Street Journal …Continue Reading about Pharma News 10_03 →